

# PEOPLE



**Jacquelyn "Jackie" Fouse** (left) has been appointed as a director of Agios Pharmaceuticals (Cambridge, MA, USA). She previously served as president and COO of Celgene until April 2017, and as a member of the company board of directors through June 2017. She joined Celgene in 2010 as CFO and was named president of the company's global hematology and oncology franchise in 2014. Before joining Celgene, Fouse served as CFO of global agribusiness and food company Bunge Limited.

"Through her tenure at Celgene, we had the privilege of working with Jackie and seeing firsthand the value she brings to a growing biotechnology company, so we are thrilled to welcome her to the Agios board of directors," said Agios CEO David Schenkein. "Jackie's guidance will be critical as we continue to build a sustainable, research-driven biopharmaceutical company with the goal of making important medicines for patients."



**Gamil Cell** (Jerusalem and Cambridge, MA, USA) has announced the appointment of **Julian Adams** (left) as chairman and CEO, succeeding **Yael Margolin** who

will remain as president. Adams has over 30 years of drug discovery and development experience, most recently as president and CSO at Clal Biotechnology Industries and previously as president of R&D at Infinity Pharmaceuticals.

Clinical-stage biopharmaceutical company Laboratoris Sanifit (Palma, Spain) has named **Alexander M. Gold** chief medical officer and president of its US subsidiary Sanifit, based in San Diego. Gold is a cardiologist with over 16 years of experience in development of new therapies. He was most recently senior vice president and head of clinical development at Portola Pharmaceuticals.

**Jody Green** has been appointed CSO of Inflexxion (Waltham, MA, USA). She previously served as director of research administration at Denver Health/Rocky Mountain & Poison Drug Center. She has held academic appointments at Vanderbilt University Medical Center School of Nursing and the University of Colorado and Denver Health Sciences Center School of Public Health.

Synergy Pharmaceuticals (New York) has named **Troy Hamilton**, previously executive

vice president, chief commercial officer, as CEO. Hamilton joined Synergy in July 2015. Previous president, CEO and chairman **Gary S. Jacob** has assumed the position of executive chairman of the board of directors.

**Prisca Havranek-Kosicek** has been appointed CFO of Novozymes (Copenhagen), effective February 1, 2018. She served as CFO and member of the executive board for Kuoni Group until November 2017. From 2011 to 2016, Havranek-Kosicek held positions at Royal DSM, including group treasurer and CFO for DSM's pharmaceutical division.

ORIC Pharmaceuticals (San Francisco) has announced the appointment of **Rich Heyman** as acting CEO and **Leonard Reyno** as executive vice president and chief medical officer. Heyman has over 25 years of experience in biopharma, previously serving as CEO of Seragon Pharmaceuticals, co-founder and CEO of Aragon Pharmaceuticals, co-founder and CSO of X-Ceptor Therapeutics, and vice president of research at Ligand Pharmaceuticals. Reyno most recently served as senior vice president and chief medical officer at Agensys, a subsidiary of Astellas Pharma.

**Annalisa Jenkins** has been named as a non-executive board member of clinical-stage vascular health company Thrombolytic Science (Cambridge, MA, USA). Jenkins brings over 25 years of global pharmaceutical industry experience to the board. She

previously served as president and CEO of Dimension Therapeutics and executive vice president, head of global R&D for Merck Serono, where she led global medical affairs and quality, and was a member of Merck Serono's pharmaceutical executive committee.

Aptinyx (Evanston, IL, USA) has appointed **Andy Kidd** chief commercial officer. Kidd has over 15 years of corporate experience in the life sciences. Prior to joining Aptinyx, he was senior vice president of strategy and business development for Baxter International.

Genome editing company Intellia Therapeutics (Cambridge, MA, USA) has named **John Leonard** president and CEO, succeeding founding president and CEO **Nessan Bermingham**, who is returning to the venture capital industry. Leonard was Intellia's founding chief medical officer and served on the board of directors. In 2016, he became executive vice president of R&D.

**Andrew Oh** has been appointed CFO of Rubius Therapeutics (Cambridge, MA, USA). Oh brings to Rubius more than 20 years of experience in finance and the biopharmaceutical industry. He was most recently chief investment officer and COO at Leerink Pharmaceutical Investments, a subsidiary of Leerink Capital Partners. Prior to Leerink, he was a senior analyst covering pharmaceutical companies at Fidelity Investments.



Aura Biosciences (Cambridge, MA, USA) has announced the appointment of **Cadmus Rich** (left) as chief medical officer. Rich joins Aura from Inotek Pharmaceuticals, where he was vice

president, medical affairs and clinical development. In addition, Aura announced that **Alison Lawton** has resigned from her role as COO to pursue other opportunities. She will remain an advisor to the company.